BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study
Entity
UAM. Departamento de MedicinaPublisher
Springer OpenDate
2019-12-21Citation
10.1186/s41687-019-0161-y
Journal of Patient-Reported Outcomes 3 (2019): 72
ISSN
2509-8020DOI
10.1186/s41687-019-0161-yFunded by
This work was sponsored by GEICAM and Novartis. Roche funded the publication fees for this articleEditor's Version
https://doi.org/10.1186/s41687-019-0161-ySubjects
Metastatic breast cancer; Bone metastasis; Quality of life; Psychometric; Treatment; Assessments; MedicinaRights
© The Author(s). 2019Abstract
Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.
Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.
Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.
BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients
Files in this item
Google Scholar:Barnadas, A.
-
Muñoz, M.
-
Margelí, M.
-
Chacón, J.I.
-
Cassinello, J.
-
Antolin, S.
-
Adrover, E.
-
Ramos, M.
-
Carrasco, E.
-
Jimeno, M.A.
-
Ojeda, B.
-
González, X.
-
González, S.
-
Conslenla, M.
-
Florián, J.
-
Miguel, A.
-
Llombart, A.
-
Lluch, A.
-
Ruiz-Borrego, M.
-
Colomer Bosch, Ramón
-
Del Barco, S.
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
Fernández de Larrea-Baz, Nerea; Pérez-Gómez, Beatriz; Guerrero-Zotano, Ángel; Casas, Ana María; Bermejo, Begoña; Baena-Cañada, José Manuel; Antolin, Silvia; Sánchez-Rovira, Pedro; Ramos Vázquez, Manuel; Garcia-Sáenz, José Ángel; Antón, Antonio; Muñoz, Montserrat; de Juan, Ana; Jara, Carlos; Chacón, José Ignacio; Arcusa, Angels; Gil-Gil, Miguel; Adrover, Encarna; Oltra, Amparo; Brunet, Joan; González, Sonia; Bezares, Susana; Lope, Virginia; Martín, Miguel; Pollán Santamaría, Marina Anunciación
2020-05-08 -
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Âlamo III" retrospective study
Márquez-Rodas, Iván; Pollán Santamaría, Marina Anunciación; Escudero, María José; Ruiz, Amparo; Martín, Miguel; Santaballa, Ana; Martínez del Prado, Purificación; Batista, Norberto; Andrés, Raquel; Antón, Antonio; Llombart, Antonio; Fernández Aramburu, Antonio; Adrover, Encarnación; González, Sonia; Seguí, Miguel Ángel; Calvo, Lourdes; Lizón, José; Rodríguez Lescure, Álvaro; Ramón y Cajal, Teresa; Llort, Gemma; Jara, Carlos; Carrasco, Eva; López-Tarruella, Sara
2017-10-05